Related Experiment Video

Updated: Aug 15, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Newer antifungal agents

Walid Abuhammour1, Eyassu Habte-Gaber

  • 1Department of Pediatrics, Hurley Medical Center, Michigan State University-College of Human Medicine, Flint, Michigan 48503-5993, USA. wabuham1@hurleymc.com

Indian Journal of Pediatrics
|April 15, 2004
PubMed

Insights

Invasive fungal infections are a major threat, especially in vulnerable populations. Newer antifungal drugs like lipid-based amphotericin B, voriconazole, and caspofungin offer improved treatment options.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections (IFIs) cause significant morbidity and mortality, particularly in premature infants, immunocompromised children, and patients on immunosuppressants.
  • Amphotericin B, discovered in 1955, has been a primary antifungal treatment.
  • Recent advancements have expanded antifungal options, including novel formulations and drug classes.

Purpose of the Study:

  • To review recent developments in antifungal therapies.
  • To discuss the clinical utility of lipid-based amphotericin B, voriconazole, and caspofungin.

Main Methods:

  • Literature review of antifungal drug development and clinical applications.
  • Discussion of pharmacological properties and therapeutic uses of key antifungal agents.

Main Results:

  • Development of less toxic lipid-based amphotericin B formulations.
  • Introduction of voriconazole, an advanced triazole antifungal.
  • Advent of echinocandin lipopeptides, exemplified by caspofungin.

Conclusions:

  • The antifungal armamentarium has significantly expanded in the last decade.
  • Lipid-based amphotericin B, voriconazole, and caspofungin represent important therapeutic advancements for IFIs.
  • These newer agents offer improved safety and efficacy profiles for managing invasive fungal infections.

More Related Videos

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Quantifying the Antifungal Activity of Peptides Against Candida albicans06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...